<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Pathogenesis of Graves' disease</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Pathogenesis of Graves' disease</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Pathogenesis of Graves' disease</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Terry F Davies, MD, FRCP, FACE</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Douglas S Ross, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jean E Mulder, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Nov 15, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Graves' disease is a syndrome that may consist of hyperthyroidism, goiter, thyroid eye disease (TED; Graves' orbitopathy), and occasionally a dermopathy referred to as pretibial or localized myxedema (PTM). The terms Graves' disease and hyperthyroidism are not synonymous, because some patients may have an orbitopathy but no hyperthyroidism, and there are other causes of hyperthyroidism in addition to Graves' disease.</p><p>Nevertheless, hyperthyroidism is the most common feature of Graves' disease, affecting nearly all patients, and is caused by autoantibodies to the thyrotropin receptor (TRAb) that activate the receptor, thereby stimulating thyroid hormone synthesis and secretion as well as thyroid growth (causing a diffuse goiter). The presence of TRAb in serum and eye involvement on clinical examination immediately distinguishes the disorder from other causes of hyperthyroidism. Other causes of an overactive thyroid gland are discussed separately. (See  <a class="medical medical_review" href="/d/html/7871.html" rel="external">"Disorders that cause hyperthyroidism"</a>.)</p><p>This topic will review the immune pathogenesis of Graves' thyroid disease, with emphasis on the role of B and T cells in the production of the TRAb that are responsible for the thyroid stimulation and growth. The pathogenesis of TED and pretibial myxedema are reviewed separately. (See  <a class="medical medical_review" href="/d/html/7825.html" rel="external">"Clinical features and diagnosis of thyroid eye disease"</a> and  <a class="medical medical_review" href="/d/html/7826.html" rel="external">"Pretibial myxedema (thyroid dermopathy) in autoimmune thyroid disease"</a>.)</p><p class="headingAnchor" id="H1665815823"><span class="h1">THE THYROID GLAND IN GRAVES' DISEASE</span><span class="headingEndMark"> — </span>The thyroid is usually, but not always, diffusely enlarged. The histology of the thyroid gland in patients with Graves' hyperthyroidism is characterized by follicular hyperplasia, intracellular colloid droplets, cell scalloping, a reduction in follicular colloid, and a patchy (multifocal) lymphocytic infiltration. Only rarely are lymphoid germinal centers seen. The histologic picture may be greatly influenced by pretreatment with antithyroid drugs, causing an underestimation of the degree of lymphocytic infiltration  (<a class="graphic graphic_picture graphicRef59711" href="/d/graphic/59711.html" rel="external">picture 1</a>). The majority of intrathyroidal lymphocytes are T cells but plenty of B cells may be present, though nothing like that seen in chronic autoimmune thyroiditis (Hashimoto's disease). In some areas, thyroid epithelial cell size correlates with the intensity of the lymphocytic infiltrate, suggesting thyroid-cell stimulation by local B cells secreting stimulating TRAb [<a href="#rid1">1</a>]. In addition, scattered, small areas of thyroid cell apoptosis may be found if stained for appropriately [<a href="#rid2">2,3</a>].</p><p class="headingAnchor" id="H2"><span class="h1">THE TSH RECEPTOR</span><span class="headingEndMark"> — </span>In Graves' disease, the main autoantigen is the thyroid-stimulating hormone (TSH, thyrotropin) receptor (TSHR)  (<a class="graphic graphic_figure graphicRef65511" href="/d/graphic/65511.html" rel="external">figure 1</a>), which is expressed primarily in the thyroid but also in adipocytes, fibroblasts, bone cells, brain tanycytes and a variety of additional cells [<a href="#rid4">4-6</a>]. Briefly, the TSHR is a G-protein coupled receptor with seven transmembrane-spanning domains responsible for signal transduction. TSH, acting via the TSHR, regulates thyroid growth and thyroid hormone production and secretion. The TSHR undergoes complex post-translational processing involving dimerization and intramolecular cleavage; the latter modification leaves a two-subunit structural form of the receptor. Data suggest that there is eventual shedding or degradation of the TSHR ectodomain [<a href="#rid7">7</a>], although this has not been demonstrated in vivo. Each of these post-translational events may influence the antigenicity of the receptor and the shed ectodomain fragment is considered the most antigenic region of the receptor. However, factors that contribute to TSHR presentation as a target for the immune system in humans are not well understood but are considered to be primarily factors that build on a state of enhanced genetic susceptibility combined with a failure of immune tolerance. Such susceptibility may be translated by variable expression of the TSHR on thymic epithelial cells, which is of great importance in determining self-tolerance [<a href="#rid8">8,9</a>].</p><p class="headingAnchor" id="H4"><span class="h1">THYROID AUTOANTIBODIES</span><span class="headingEndMark"> — </span>It is well known that lymphocytes from Graves' thyroid tissue spontaneously secrete thyroid autoantibodies, including thyrotropin receptor antibodies (TRAb), in vitro, providing evidence of their activated state [<a href="#rid10">10</a>]. Additional evidence for their presence and activated state comes from the decline in serum thyroid autoantibody concentrations after antithyroid drug treatment, after thyroidectomy, and late after radioiodine therapy (see <a class="local">'Influence of radioiodine on TRAb'</a> below). In particular, B cells are excellent presenters of antigen to T cells, and it is likely that a primary function of thyroid autoantibodies on the surface of B cells is to home the B cell to the thyroid gland, where it obtains thyroid antigens and presents them to the T cells.</p><p class="headingAnchor" id="H5"><span class="h2">Autoantibodies to the TSH receptor</span><span class="headingEndMark"> — </span>Over 50 years ago, serum from patients with Graves' hyperthyroidism was found to contain a long-acting thyroid stimulator (LATS) later shown to be confined to the immunoglobulin fraction of the serum [<a href="#rid11">11</a>]. LATS inhibited the binding of radiolabeled TSH to thyroid membranes, suggesting that such activity was due to the presence of an antibody to the TSH receptor (now often called TRAb) [<a href="#rid12">12</a>].</p><p>The first proof that TRAb stimulated the thyroid gland in humans came from infusion experiments in human volunteers and later from the transient detection of TRAb in the serum of hyperthyroid neonates of mothers with Graves' disease and persisting TRAb [<a href="#rid13">13,14</a>].</p><p>Stimulating TRAb have several other characteristics:</p><p class="bulletIndent1"><span class="glyph">●</span>They are specific for autoimmune thyroid disease, especially Graves' disease, in contrast to antibodies to thyroglobulin (Tg) and thyroid peroxidase (TPO) which occur in the "normal" population. Almost all patients with Graves' hyperthyroidism have detectable TRAb when measured by sensitive assays [<a href="#rid15">15-17</a>]. TRAb can also be detected in approximately 10 percent of Hashimoto's thyroiditis patients. These antibodies are unique to humans; no animals develop Graves' disease, although it can be induced in rodents by immunization with TSHR [<a href="#rid18">18-21</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>TRAb are usually of the immunoglobulin G1 (IgG1) subclass, which suggests that they are oligoclonal [<a href="#rid22">22</a>], in contrast to antibodies to TPO and Tg, which are polyclonal. Oligoclonality is suggestive of causation while polyclonality is suggestive of a reactive response.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The serum concentrations of TRAb are relatively low to begin with and tend to decline in patients treated with an antithyroid drug. If high concentrations persist, the patient is likely to become hyperthyroid again when the drug is discontinued. However, such a reaction assumes the thyroid is capable of secreting excess thyroid hormones once again and has not been damaged by ongoing thyroiditis or the patient has iodine deficiency [<a href="#rid23">23-25</a>]. Measuring serum TRAb in these patients can be helpful, but only when the result is positive. A significant number of patients negative for TRAb after a course of antithyroid drugs will still have a recurrence [<a href="#rid26">26</a>]. In practice, we always measure serum TRAb at the time of planned cessation of drug therapy and continue the drugs if TRAb remain detectable [<a href="#rid23">23,24</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Stimulating TRAb, like TSH, enhance the synthesis and activity of the sodium-iodide symporter, explaining the increased uptake of iodide by thyroid tissue in Graves' disease in the presence of a totally suppressed TSH [<a href="#rid27">27</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>TRAb, like TSH, stimulate different subtypes of G proteins (but primarily Gs-alpha), resulting especially in increased protein kinase A (PKA) and thyroid adenylate cyclase activity, which leads to increased thyroid hormone synthesis, secretion, and cell survival. High levels of TRAb also stimulate Gq and then the protein kinase C (PKC) pathway leading to modulation of thyroid cell development and cell proliferation [<a href="#rid28">28-30</a>].</p><p></p><p>Since oligoclonal TSHR autoantibodies are the hallmark of Graves' disease, it is clear that B cells must also be important in the immune pathogenesis. This has been exemplified by the effective use of <a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">rituximab</a> (monoclonal anti-CD20) in selected patients with active TED [<a href="#rid31">31,32</a>]. These results indicate that B cells not only have a role in the hyperthyroidism of Graves' disease, but also the TED, and suggest that TRAb interactions with retroorbital TSHRs expressed on fibroblasts and adipocytes may be important in disease etiology. (See  <a class="medical medical_review" href="/d/html/7827.html" rel="external">"Treatment of thyroid eye disease"</a>.)</p><p class="headingAnchor" id="H6"><span class="h2">Influence of radioiodine on TRAb</span><span class="headingEndMark"> — </span>In patients treated with radioiodine, the serum thyrotropin receptor antibodies (TRAb) concentrations initially rise, reaching a peak three to five months after treatment, and then gradually decline [<a href="#rid33">33</a>]. The initial increase in serum antibody concentrations after radioiodine therapy may explain why, in some patients, TED may first appear or may transiently worsen afterwards (see  <a class="medical medical_review" href="/d/html/7827.html" rel="external">"Treatment of thyroid eye disease"</a>). The TRAb may then either gradually decline or, more commonly, persist for many years after radioiodine treatment [<a href="#rid34">34</a>]. Although it is theoretically possible for extrathyroidal TSHRs to act as antigenic stimuli in the absence of the thyroid, TRAb soon fall after thyroidectomy and disappear in 70 to 80 percent of patients after 18 months [<a href="#rid34">34</a>].</p><p class="headingAnchor" id="H7"><span class="h2">Different types of TRAb</span><span class="headingEndMark"> — </span>Not all thyrotropin receptor antibodies (TRAb) are stimulatory. Some, including those found in the serum of patients with Hashimoto's thyroiditis, block the binding and action of TSH and, therefore, can cause hypothyroidism  (<a class="graphic graphic_figure graphicRef71144" href="/d/graphic/71144.html" rel="external">figure 2</a>). Blocking TRAb can be found in 10 to 15 percent of Hashimoto's patients. However, some patients with Graves' disease have a mixture of TRAb, both stimulating and blocking, and the clinical presentation may depend upon a balance between these different antibodies. A third group of TRAb used to be called neutral TRAb, and they bind to the hinge region of the receptor, which connects the ectodomain to the transmembrane domain, and they do not influence TSH binding. These antibodies can in fact have cell-signaling capability, inducing thyroid cell stress and even apoptosis. They are better referred to as hinge-region TRAb, reflecting the region on the TSHR to which they are directed but remain of uncertain clinical significance [<a href="#rid35">35,36</a>]. Evidence of their potential role comes from a mouse model where such neutral antibodies induced thyroid cell stress and apoptosis [<a href="#rid37">37,38</a>].</p><p class="headingAnchor" id="H8"><span class="h2">Binding sites for TRAb</span><span class="headingEndMark"> — </span>Stimulating and blocking TSHR antibodies (S-TRAb and B-TRAb) bind to a complex conformational epitope on the extracellular domain of the TSHR, principally in the region of the receptor to which TSH binds, which is a binding pocket encompassing the leucine-rich repeat region  (<a class="graphic graphic_figure graphicRef65511" href="/d/graphic/65511.html" rel="external">figure 1</a>) [<a href="#rid39">39</a>]. The differences in functional activity of TRAb (stimulating, blocking, or "neutral") relate to their variable molecular binding characteristics, resulting in different cell-signaling initiatives. Stimulating TRAb only have affinity for a conformational epitope in the ectodomain with approximately a dozen binding sites and will not interact with an unfolded/reduced receptor molecule [<a href="#rid4">4</a>]. Shedding of the subunit of the TSHR extracellular domain into the extracellular fluid may be an important antigenic stimulus for TRAb formation. Only a minority of TRAb bind to linear epitopes, and these are likely to be of the blocking or neutral variety [<a href="#rid40">40-43</a>].</p><p class="headingAnchor" id="H9"><span class="h2">Relationship between Graves' disease and autoimmune thyroiditis</span><span class="headingEndMark"> — </span>Lymphocytic infiltration of the thyroid and the presence of anti-Tg and anti-TPO antibodies in the serum occur in both Graves' disease and chronic autoimmune (Hashimoto's) thyroiditis, suggesting that the two disorders are related in fundamental ways and consistent with their appearance within the same family and their sharing of a number of susceptibility genes including human leukocyte antigen (HLA) (see  <a class="medical medical_review" href="/d/html/7854.html" rel="external">"Pathogenesis of Hashimoto's thyroiditis (chronic autoimmune thyroiditis)"</a>). Therefore, it appears that Graves' disease may often develop on a background of thyroiditis. Several other observations support this hypothesis:</p><p class="bulletIndent1"><span class="glyph">●</span>Areas of cellular apoptosis may be seen even in Graves' thyroid glands [<a href="#rid2">2,3</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The presence of antibodies that bind to the TSHR can be found in both disorders.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Progression from Graves' hyperthyroidism to chronic autoimmune thyroiditis and hypothyroidism is well recognized [<a href="#rid44">44</a>]. The converse also occurs [<a href="#rid45">45</a>], and there are patients who have hypothyroidism one year, Graves' hyperthyroidism another, and hypothyroidism again later [<a href="#rid46">46</a>]. This clinical presentation is sometimes called Graves' alternans.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In families of patients, some members may have Graves' disease and others may have chronic autoimmune thyroiditis [<a href="#rid47">47</a>].</p><p></p><p class="headingAnchor" id="H11"><span class="h1">T CELLS IN GRAVES' DISEASE</span><span class="headingEndMark"> — </span>T cells are present in the immune repertoire of patients with Graves' disease that react with appropriately processed peptides derived from all thyroid autoantigens. These activated T cells in turn release a variety of cytokines causing inflammation and an increase the secretion of thyroid-specific autoantibodies from B cells.</p><p>The current concept is that thyroid-specific T cells in Graves' disease primarily act as helper (CD4+ Th1) cells. However, distinct subsets of T cells have been identified that are distinguished most easily by the cytokines that they produce  (<a class="graphic graphic_table graphicRef53741" href="/d/graphic/53741.html" rel="external">table 1</a>):</p><p class="bulletIndent1"><span class="glyph">●</span>CD4+ Th1 cells – When activated, these cells secrete interleukin-2 (IL-2), interferon gamma (IFN-gamma), and tumor necrosis factor (TNF)-alpha, which in turn activate cytotoxic (CD8+) cells and may induce thyroid cell apoptosis.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>CD4+ Th2 cells – These cells secrete IL-4 and IL-5 (but not IFN-gamma) and activate antibody production, amongst other actions.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>CD4+ Th17 cells – This proinflammatory subset of cells secretes IL-17 under the influence of IL-23.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>CD4+ Treg cells – These are the anti-inflammatory regulatory T cells (Tregs) (CD4+CD25+), which diminish the activity of Th1 and Th2 cells [<a href="#rid48">48</a>]. One characteristic of Treg cells is the expression of the transcription factor Foxp3.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>CD8+ cytotoxic cells – These act primarily as destructive T cells under the control of Th2 and Treg cells.</p><p></p><p>While all types of T cells are found in the thyroid glands of patients with Graves' hyperthyroidism, it is helpful to consider Graves' disease as a mixture of Th1 and Th2 autoimmune responses. As far as Graves' disease is concerned, the primary pathophysiology is related to the TSHR antibodies (TRAb) of the immunoglobulin G1 (IgG1) subclass, which are driven by IFN-gamma [<a href="#rid49">49,50</a>]. Moreover, the Th1 and Th2 types of T helper cells interact with each other so that a predominance of, for example, Th1 cells does not necessarily mean that the predominant result is apoptosis. T cells may induce target cell death directly, and there is some evidence for a minor degree of thyroid-cell apoptosis in Graves' disease [<a href="#rid2">2,3</a>]. In the past, we have identified a clone of T cells that specifically lysed autologous thyroid cells from a patient with goitrous autoimmune thyroiditis (Hashimoto's disease), but we were unable to identify similar cells in patients with Graves' hyperthyroidism [<a href="#rid51">51</a>]. This suggests that thyroid antibodies may be involved in the thyroid cell death that occurs in Graves' thyroid glands, and we have suggested that the neutral region TRAb may be responsible [<a href="#rid36">36</a>]. In contrast, there are extensive data on the importance of apoptosis in the thyroid destruction of Hashimoto's disease. Such apoptotic cells enhance the immune response [<a href="#rid52">52</a>]. (See  <a class="medical medical_review" href="/d/html/7854.html" rel="external">"Pathogenesis of Hashimoto's thyroiditis (chronic autoimmune thyroiditis)"</a>.) </p><p class="headingAnchor" id="H12"><span class="h2">Mechanisms of T cell activation</span><span class="headingEndMark"> — </span>The T cell receptor sees antigen in the context of human leukocyte antigen (HLA). This means that the T cell receptor complexes with an HLA molecule on the surface of an antigen-presenting cell  (<a class="graphic graphic_figure graphicRef69555" href="/d/graphic/69555.html" rel="external">figure 3</a>); CD8+ cells bind with HLA class I molecules and CD4+ cells bind with HLA class II molecules. This complex forms only when the appropriate antigenic peptide (for example from the TSH receptor [TSHR]) is present in the binding pocket of the HLA molecule. Data show that binding pocket residue Arg74 is important for the binding of thyroid-related peptides, and helps explain the HLA association with Graves' disease [<a href="#rid53">53</a>]. Once this complex is formed, the T cell requires an additional stimulus to proliferate and secrete cytokines. This additional stimulus is called "costimulation" and is provided by costimulatory molecules on the same T cell and antigen-presenting cells  (<a class="graphic graphic_table graphicRef62994" href="/d/graphic/62994.html" rel="external">table 2</a>) [<a href="#rid54">54</a>]. If no costimulation occurs, the T cell may become anergic or even apoptotic. Thyroid cells express major histocompatibility complex (MHC) molecules in autoimmune thyroid disease and may express costimulatory molecules (such as CD40), aiding in intrathyroidal T cell activation.</p><p class="headingAnchor" id="H13"><span class="h2">Changing the T cell population</span><span class="headingEndMark"> — </span>Perturbing the T cell repertoire, in particular, disrupting the Treg cells, can result in Graves' hyperthyroidism in susceptible patients by facilitating production of TRAb. In a group of 27 patients with multiple sclerosis (a Th1-predominant disease) treated with a monoclonal antibody to T cells, peripheral blood CD4+ and CD8+ T cell counts fell to less than 20 percent of normal for at least 18 months and multiple sclerosis disease activity decreased in all patients, but nine developed Graves' hyperthyroidism 6 to 31 months after treatment [<a href="#rid55">55</a>]. Graves' hyperthyroidism has also occasionally been a complication of interferon alfa treatment in patients with hepatitis C, again thought to be on the basis of changes in T cell repertoire [<a href="#rid56">56</a>]. The same explanation is given for the improvement in Graves' disease by the onset of pregnancy where the action of Treg cells is enhanced [<a href="#rid57">57</a>]. Similarly, the improvement in TED following corticosterone therapy has been suggested as secondary to changes in the Th17/Treg ratio [<a href="#rid58">58</a>].</p><p class="headingAnchor" id="H14"><span class="h2">Intrathyroidal T cell receptor V gene repertoire</span><span class="headingEndMark"> — </span>As discussed above, T cells are activated by the binding of complexes of HLA (major histocompatibility molecules) and antigenic peptides processed from proteins by antigen-processing cells. These complexes bind to antigen receptors on the surface of T cells. These receptors consist of two noncovalently linked chains (alpha and beta), each with variable (V), diversity (D), and junctional (J) regions and common constant regions. The V, D, and J genes code for the sites on the receptors that recognize the HLA-antigen complex, affording antigenic specificity. In addition to the many V (&gt;100) and J (&gt;50) genes present in the genome, random nucleotide additions and deletions to the D region add immense complexity to the T cell antigen receptor repertoire, causing this region to be the major site of antigen recognition [<a href="#rid59">59</a>]. Evidence for an etiologic role for T cells in Graves' hyperthyroidism is the finding that the antigen receptors of T cells isolated from thyroid tissue are the products of a limited number of V gene families [<a href="#rid60">60-62</a>]. This observation suggests that the thyroid tissue of these patients attracts and activates T cells with particular types of antigen receptors, rather than nonspecifically.</p><p>In support of this concept is evidence for clonally expanded T cell populations within the thyroid gland in Graves' disease. These data have been obtained by direct sequencing of the genes for T cell antigen receptors from intrathyroidal T cells [<a href="#rid62">62-64</a>]. These results indicate limited T cell heterogeneity in Graves' disease and point to the primacy of T cells in disease etiology. The findings are similar to those in synovial tissue from patients with rheumatoid arthritis and central nervous system plaques from patients with multiple sclerosis [<a href="#rid65">65</a>]. However, as the pathologic process progresses, there is likely to be a less restricted response [<a href="#rid66">66</a>].</p><p class="headingAnchor" id="H15"><span class="h2">The role of suppressor effects of T cells</span><span class="headingEndMark"> — </span>We now understand that the immune system exerts some of its overall control via Treg (CD4+CD25+Foxp3+) cells which exert "suppression" by cytokine secretion and cell-cell contact. This function may be diminished in Graves' disease, although not all studies have found this [<a href="#rid67">67,68</a>]; caution is needed since T regulatory function may be decreased by high thyroid hormone levels [<a href="#rid69">69</a>]. The ratio of Th17/Treg is often used as an assessment of Treg function since absolute numbers vary quite widely between individuals. </p><p>Even if there were only subtle defects in regulatory T cell function in patients with Graves' hyperthyroidism, the phenomena of deletion and anergy will also contribute to antigen-specific tolerance [<a href="#rid70">70,71</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Deletion of immune cells via apoptosis occurs when immature T and B cells bind antigens in the absence of costimulatory molecules.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Anergy can also occur when mature immune cells bind antigen in the absence of co-stimulatory molecules, leading to desensitization rather than deletion.</p><p></p><p class="headingAnchor" id="H16"><span class="h1">IMMUNE MECHANISMS OF DISEASE</span><span class="headingEndMark"> — </span>The cause of Graves' disease is not known. There are a variety of immune mechanisms that may be involved in the pathogenesis of Graves' hyperthyroidism, but these remain hypotheses. The major mechanisms for which there is some evidence are molecular mimicry (specificity crossover), thyroid-cell expression of HLA (human leukocyte-associated) molecules (antigens), and bystander activation. All of these mechanisms involve a failure to maintain tolerance to the TSHR.</p><p class="headingAnchor" id="H17"><span class="h2">Molecular mimicry</span><span class="headingEndMark"> — </span>Molecular mimicry implies structural similarity between some infectious or other exogenous agent and human proteins, such that antibodies and T cells activated in response to the exogenous agent react with a human self-thyroid protein. As an example, in an analysis of 600 monoclonal antibodies raised against a large variety of viruses, 4 percent of the monoclonal antibodies cross-reacted with uninfected tissues [<a href="#rid72">72</a>]. However, with respect to Graves' hyperthyroidism, there is no strong evidence that molecular mimicry plays a role. The suggestive evidence is:</p><p class="bulletIndent1"><span class="glyph">●</span>The serum of some patients contains antibodies that react with antigens derived from <em>Yersinia enterocolitica </em>[<a href="#rid73">73</a>]. Furthermore, serum from some patients recovering from Yersinia infections blocks the binding of TSH to its receptors. In addition, in a report of twins discordant for Graves' disease, the twin with Graves' disease had an increased odds ratio of prior Yersinia infection [<a href="#rid74">74</a>]. However, patients who have or have had infections with these organisms do not have thyroid dysfunction.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Structural similarities between retroviral sequences and the TSH receptor (TSHR) have been detected [<a href="#rid75">75</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Bacterial heat shock proteins can elicit antibody and T cell responses, which may cross-react with host heat shock proteins. Heat shock protein 72 has been reported in thyroid tissue from patients with Graves' hyperthyroidism but not in thyroid tissue from normal subjects [<a href="#rid76">76</a>].</p><p></p><p>Of note, this use of the term molecular mimicry should not be confused with the relationship between hyperthyroidism and TED in Graves' disease, where it is likely that the two tissues contain the same antigen, the TSHR, so that a crossover immune reaction against the thyroid antigen affects the retroorbital tissues. (See  <a class="medical medical_review" href="/d/html/7825.html" rel="external">"Clinical features and diagnosis of thyroid eye disease"</a>.)</p><p class="headingAnchor" id="H18"><span class="h2">Thyroid cell expression of HLA molecules</span><span class="headingEndMark"> — </span>Thyroid epithelial cells from patients with autoimmune thyroid disease (including Graves' disease), but not normal subjects, express major histocompatibility complex (MHC) human leukocyte antigen (HLA) class II molecules, notably HLA-DR molecules  (<a class="graphic graphic_picture graphicRef59711" href="/d/graphic/59711.html" rel="external">picture 1</a>) in addition to enhanced expression of HLA class I. This expression could be the direct result of viral or other infections of thyroid epithelial cells, or it may be induced by cytokines such as interferon gamma (IFN-gamma) produced by T cells that have been attracted to the gland either by an infection or directly because of the presence of thyroid antigens [<a href="#rid77">77</a>]. The potentially important role of interferon alpha, which may be induced by viral infection, further supports the concept of viral involvement [<a href="#rid78">78</a>].</p><p>Class II molecule expression provides a mechanism for presentation of thyroid antigens to autoreactive T cells resulting in their activation and with the potential for persistence of thyroid disease. Several experimental observations provide support for this hypothesis:</p><p class="bulletIndent1"><span class="glyph">●</span>Induction of class II molecules on thyroid epithelial cells by interferon gamma can induce autoimmune thyroiditis in susceptible mice [<a href="#rid79">79</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Viruses can directly induce class II molecule expression on thyroid cells, independent of cytokine secretion [<a href="#rid80">80,81</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Thyroid epithelial cells expressing class II molecules can present viral peptide antigens to cloned T cells [<a href="#rid82">82</a>]. Thyroid antigen-specific T cell clones in normal rats react specifically with cloned autologous thyroid cells in the absence of more conventional antigen-presenting cells [<a href="#rid83">83</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>An animal model of Graves' disease induced by cells expressing the TSHR is only effective when the cells also express MHC class II antigens [<a href="#rid18">18,19</a>].</p><p></p><p>These findings support the view that an insult, such as infection, may induce class II molecule expression on human thyroid cells and that these cells then may act as antigen-presenting cells to initiate an autoimmune response. The expression of a T cell costimulator molecule, CD40, on thyroid epithelial cells indicates that costimulatory molecules are available for this action. In addition, intrathyroidal dendritic cells and B cells may also serve as potent antigen-presenting cells [<a href="#rid54">54</a>]. The description of hyperthyroidism in mice immunized with fibroblasts coexpressing class II molecules and human TSHRs provides further evidence that cells need not be "professional" antigen-presenting cells to present antigen so long as they can acquire the ability to express class II molecules [<a href="#rid18">18</a>].</p><p>However, the context in which HLA class II is induced by cytokines is of prime importance. As an example, transgenic mice with thyroid cells which secrete IFN-gamma showed limited thyroiditis even in susceptible strains, and this may be due to the too high local concentration of IFN-gamma [<a href="#rid66">66</a>].</p><p class="headingAnchor" id="H19"><span class="h2">Bystander activation</span><span class="headingEndMark"> — </span>In order for this model of HLA class II antigen expression and presentation of antigens to be realized, there must be a local insult to initiate the responses. As mentioned above, this may take the form of a direct insult to the thyroid by a viral infection of the thyroid cells or of immune cells. Even the arrival of activated T cells within the thyroid gland may perhaps initiate such a series of events in a susceptible subject with the appropriate immune repertoire. Evidence has mounted that such bystander activation of local T cells, which may not be thyroid specific, may exert via cytokines a marked activation effect on resident thyroid-specific T cells. Evidence for such bystander effects has been obtained in an animal model of viral-induced autoimmune insulitis [<a href="#rid84">84</a>] and in experimental autoimmune thyroiditis [<a href="#rid85">85</a>]. The attractiveness of this sequence of events is that many different types of infections would lead to the same clinical disease phenotype.</p><p class="headingAnchor" id="H20"><span class="h1">PRECIPITATING AND PREDISPOSING FACTORS</span><span class="headingEndMark"> — </span>Several factors that predispose to Graves' hyperthyroidism have been proposed  (<a class="graphic graphic_table graphicRef55200" href="/d/graphic/55200.html" rel="external">table 3</a>).</p><p class="headingAnchor" id="H21"><span class="h2">Genetic susceptibility</span><span class="headingEndMark"> — </span>There is abundant epidemiologic evidence for genetic susceptibility to Graves' hyperthyroidism and chronic autoimmune thyroiditis  (<a class="graphic graphic_table graphicRef53775" href="/d/graphic/53775.html" rel="external">table 4</a>) [<a href="#rid86">86-88</a>].</p><p class="bulletIndent1"><span class="glyph">●</span>The diseases cluster in families and are more common in females.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The concordance rate in monozygotic twins is 20 to 40 percent.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The sibling recurrence rate for Graves' disease exceeds 10.0 [<a href="#rid89">89</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>There are weak associations with a number of immune-related genes which have also been found with many other autoimmune diseases and presumably underpin the inherited susceptibility to autoimmunity; for example, with certain alleles of cytotoxic T lymphocyte-associated (CTLA)-4 [<a href="#rid88">88,90</a>]. As an example, in one study of 379 patients with Graves' hyperthyroidism in the United Kingdom, 42 percent had a particular allele (G allele) of the cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) gene, as compared with 32 percent of 363 normal subjects [<a href="#rid88">88,90</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In keeping with an immune-related susceptibility seen in almost all autoimmune diseases, there is a well-known association with certain alleles of human leukocyte antigen (HLA) on chromosome 6 [<a href="#rid86">86</a>]. As an example, a study of White patients in North America found that HLA-DRB1*08 and DRB3*0202 were associated with the disease and that DRB1*07 was protective [<a href="#rid91">91</a>]. Detailed studies have shown convincingly that the presence of Arg74 is the important peptide in the HLA DR binding pocket rather than just the HLA subtype [<a href="#rid53">53,92</a>]. As far as thyroid-specific gene associations are concerned, there is now evidence of increased risks associated with polymorphisms of intron 1 in the TSH receptor (TSHR) gene [<a href="#rid93">93-96</a>] and the thyroglobulin (Tg) gene [<a href="#rid97">97</a>]. The data suggest that the influence of HLA and Tg polymorphisms is more than additive.</p><p></p><p class="bulletIndent1">The associated risks with these gene associations are all relatively low so that their assessment is not currently clinically useful, nor do they allow us to conclude which are the major genes associated with Graves' disease. HLA remains the strongest association. However, the new era of screening for postzygotic mutations may reveal stronger linkages in the future [<a href="#rid98">98</a>].</p><p></p><p class="headingAnchor" id="H22"><span class="h2">Infection</span><span class="headingEndMark"> — </span>Autoimmune thyroiditis can be induced in experimental animals by certain viral infections. If infection were the direct cause of Graves' hyperthyroidism, an identifiable agent should be present in the majority of patients, and it should be possible to induce the disease by transferring the agent. Possible infections of the thyroid gland itself (eg, subacute thyroiditis, congenital rubella) have been associated with thyroid autoimmune disease and could initiate class II molecule expression. Hepatitis C infection is a well-recognized precipitator of autoimmune thyroid disease when treated with interferon therapy, although, most commonly, a thyroiditis develops rather than Graves' disease [<a href="#rid99">99</a>]. A report of retroviral sequences in the thyroid glands of patients with Graves' disease was not confirmed [<a href="#rid100">100,101</a>]. With the coronavirus 2019 (COVID-19) pandemic, there have been a few case reports trying to associate infection with Graves' disease [<a href="#rid102">102,103</a>]. While there may be a weak association with subacute thyroiditis, there is no good evidence of a connection with Graves' disease other than chance. There is also no evidence that any other infections or exposures lead directly to autoimmune thyroid disease in the majority of patients [<a href="#rid104">104</a>], although examination of thyroid tissue from patients with Hashimoto's and Graves' diseases continues to yield suspicious evidence [<a href="#rid105">105,106</a>].</p><p class="headingAnchor" id="H23"><span class="h2">Stress</span><span class="headingEndMark"> — </span>As compared with normal subjects or patients with toxic nodular goiter, patients with Graves' hyperthyroidism more often give a history of some type of psychologic stress, in particular negative life events such as loss of a spouse or a road traffic accident, before the onset of their hyperthyroidism [<a href="#rid107">107-109</a>]. In general, stress appears to induce a state of immune suppression, possibly mediated by the actions of cortisol on immune cells. Stress-induced suppression may be followed by rebound immunologic hyperactivity. Such a response could precipitate autoimmune thyroid disease in genetically susceptible subjects.</p><p class="headingAnchor" id="H24"><span class="h2">Biological sex</span><span class="headingEndMark"> — </span>More females develop Graves' hyperthyroidism than males, with a ratio of approximately 4:1, an effect that is often said to be mediated in some way by more estrogen or less testosterone. There is a large body of evidence that moderate amounts of estrogen enhance immunologic reactivity [<a href="#rid110">110-112</a>]. However, it is just as likely that the extra X chromosome is the source of the enhanced susceptibility rather than sex steroids since the susceptibility continues after the menopause. For example, X chromosome inactivation has been associated with autoimmune thyroid disease [<a href="#rid113">113</a>]. We are also learning of sex differences in the immune response, for example in natural killer cell responses, which may indicate significant differences in male and female reactions to immune insults [<a href="#rid114">114</a>].</p><p class="headingAnchor" id="H4074676221"><span class="h2">Microbiota</span><span class="headingEndMark"> — </span>The gut microbiome is required for normal immune system maturation, especially induction of tolerance. Alterations in bacterial function and diversity likely contributes to autoimmune diseases. Studies in mice have demonstrated that early life microbial exposures determine sex hormone levels and modify progression to autoimmunity suggesting that the gut microbiota may contribute to autoimmune thyroid disease susceptibility [<a href="#rid115">115</a>]. Data on the gut microbiome indicate a difference in the male and female flora and also suggest an influence on Graves' disease [<a href="#rid116">116-119</a>].</p><p class="headingAnchor" id="H25"><span class="h2">Smoking</span><span class="headingEndMark"> — </span>Smoking is a risk factor for Graves' hyperthyroidism (relative risk approximately 2.0) and an even stronger risk factor for TED [<a href="#rid120">120-122</a>]. The mechanism remains uncertain, other than the obvious effect of irritation [<a href="#rid123">123</a>].</p><p class="headingAnchor" id="H26"><span class="h2">Pregnancy</span><span class="headingEndMark"> — </span>Severe Graves' disease is uncommon during pregnancy because hyperthyroidism is associated with reduced fertility and increased pregnancy loss. When severe hyperthyroidism occurs, however, it can endanger both mother and fetus. Luckily, pregnancy is a time of immune tolerance <strong>so that the disease tends to improve as pregnancy progresses</strong>. During pregnancy, both T cell and B cell functions are diminished, while regulatory T cells increase, dampening the disease [<a href="#rid57">57,124</a>]. The slow rebound from this tolerant state after delivery results in enhanced immune reactivity, and this contributes to the development of the postpartum thyroid diseases, including the new onset or recurrence of Graves' disease [<a href="#rid125">125</a>].</p><p>It has also been suggested that fetal microchimerism (the presence of fetal cells in maternal tissue) might play a role in the development of pregnancy tolerance and postpartum autoimmune thyroid disease [<a href="#rid126">126</a>]. Up to 30 percent of young females give a history of pregnancy in the 12 months before the onset of Graves' disease [<a href="#rid64">64</a>], indicating that postpartum Graves' disease is a surprisingly common presentation and that pregnancy is a major risk factor in susceptible females.</p><p class="headingAnchor" id="H27"><span class="h2">Drugs</span><span class="headingEndMark"> — </span>Iodine and iodine-containing drugs such as <a class="drug drug_general" data-topicid="8595" href="/d/drug information/8595.html" rel="external">amiodarone</a> and computed tomography (CT) scan contrast media may precipitate Graves' disease, or a recurrence of Graves' disease, in a susceptible individual [<a href="#rid127">127</a>]. Iodine is most likely to precipitate thyrotoxicosis in an iodine-deficient population simply by allowing the thyrotropin receptor antibodies (TRAb) to be effective in stimulating more thyroid hormone to be formed. Whether there is any other precipitating event is unclear. Iodine and amiodarone may also damage thyroid cells directly and release thyroid antigens to the immune system [<a href="#rid128">128</a>]. </p><p>Interferon alfa treatment of patients with hepatitis C infection has been widely associated with the development of autoimmune thyroiditis but Graves' disease may also be precipitated presumably by influencing the immune repertoire [<a href="#rid129">129</a>]. <a class="drug drug_general" data-topicid="8725" href="/d/drug information/8725.html" rel="external">Alemtuzumab</a>, a monoclonal antibody against the T cell antigen CD52 used for treatment of multiple sclerosis, has been associated with a 10 to 15 percent incidence of new-onset Graves' disease [<a href="#rid130">130</a>]. The immune checkpoint inhibitors, such as CTLA-4 and programmed cell death 1 (PD-1)/PD-1 ligand 1 (PD-L1) negatively regulate the immune system, and autoimmune thyroid disease is one of their most common side effects [<a href="#rid131">131</a>]. However, these cases are mostly autoimmune thyroiditis, and Graves' disease is much less common. (See  <a class="medical medical_review" href="/d/html/7845.html" rel="external">"Drug interactions with thyroid hormones", section on 'Checkpoint inhibitor immunotherapy'</a>.)</p><p class="headingAnchor" id="H28"><span class="h1">SUMMARY</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Overview of Graves' disease</strong> – Hyperthyroidism is the most common feature of Graves' disease, affecting nearly all patients and is caused by autoantibodies to the thyrotropin receptor (TRAb) that activate the receptor, thereby stimulating thyroid hormone synthesis and secretion and thyroid growth (causing a diffuse goiter). The presence of TRAb in the serum and thyroid eye disease (TED) on clinical examination distinguishes the disorder from other causes of hyperthyroidism. (See <a class="local">'Introduction'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>TSH receptor antibodies (TRAb</strong>) – TRAb stimulate the thyroid gland and are specific for Graves' disease, in contrast to thyroglobulin (Tg) and thyroid peroxidase (TPO) antibodies. They bind mainly to the leucine-rich repeat region of the thyroid-stimulating hormone (TSH) receptor (TSHR) ectodomain to which TSH binds  (<a class="graphic graphic_figure graphicRef65511" href="/d/graphic/65511.html" rel="external">figure 1</a>). (See <a class="local">'Autoantibodies to the TSH receptor'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>T cells in Graves' disease</strong> – T cells are present in patients with Graves' disease that react with appropriately processed peptides derived from all thyroid autoantigens but in particular the TSHR. These activated T cells in turn increase the secretion of thyroid-specific autoantibodies from B cells. Thyroid-specific T cells in Graves' disease primarily act as helper (CD4) rather than suppressor or cytotoxic (CD8) cells. (See <a class="local">'T cells in Graves' disease'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Immune mechanisms of disease</strong> – A variety of immune mechanisms may be involved in the pathogenesis of Graves' hyperthyroidism. The major mechanisms for which there is reasonable evidence are thyroid cell expression of human leukocyte antigen (HLA)-associated molecules associated with bystander activation. (See <a class="local">'Immune mechanisms of disease'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Precipitating and predisposing factors</strong> – Possible precipitating and predisposing factors include genetic susceptibility, infection, stress, smoking, pregnancy, and iodine. (See <a class="local">'Precipitating and predisposing factors'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Paschke R, Brückner N, Eck T, et al. Regional stimulation of thyroid epithelial cells in Graves' disease by lymphocytic aggregates and plasma cells. Acta Endocrinol (Copenh) 1991; 125:459.</a></li><li><a class="nounderline abstract_t">Feig C, Peter ME. How apoptosis got the immune system in shape. Eur J Immunol 2007; 37 Suppl 1:S61.</a></li><li><a class="nounderline abstract_t">Bossowski A, Czarnocka B, Bardadin K, et al. Identification of apoptotic proteins in thyroid gland from patients with Graves' disease and Hashimoto's thyroiditis. Autoimmunity 2008; 41:163.</a></li><li><a class="nounderline abstract_t">Davies TF, Ando T, Lin RY, et al. Thyrotropin receptor-associated diseases: from adenomata to Graves disease. J Clin Invest 2005; 115:1972.</a></li><li><a class="nounderline abstract_t">Latif R, Morshed SA, Zaidi M, Davies TF. The thyroid-stimulating hormone receptor: impact of thyroid-stimulating hormone and thyroid-stimulating hormone receptor antibodies on multimerization, cleavage, and signaling. Endocrinol Metab Clin North Am 2009; 38:319.</a></li><li><a class="nounderline abstract_t">Kannangara H, Cullen L, Miyashita S, et al. Emerging roles of brain tanycytes in regulating blood-hypothalamus barrier plasticity and energy homeostasis. Ann N Y Acad Sci 2023; 1525:61.</a></li><li><a class="nounderline abstract_t">Chazenbalk GD, Pichurin P, Chen CR, et al. Thyroid-stimulating autoantibodies in Graves disease preferentially recognize the free A subunit, not the thyrotropin holoreceptor. J Clin Invest 2002; 110:209.</a></li><li><a class="nounderline abstract_t">Colobran R, Armengol Mdel P, Faner R, et al. Association of an SNP with intrathymic transcription of TSHR and Graves' disease: a role for defective thymic tolerance. Hum Mol Genet 2011; 20:3415.</a></li><li><a class="nounderline abstract_t">Stefan M, Wei C, Lombardi A, et al. Genetic-epigenetic dysregulation of thymic TSH receptor gene expression triggers thyroid autoimmunity. Proc Natl Acad Sci U S A 2014; 111:12562.</a></li><li><a class="nounderline abstract_t">McLachlan SM, Pegg CA, Atherton MC, et al. TSH receptor antibody synthesis by thyroid lymphocytes. Clin Endocrinol (Oxf) 1986; 24:223.</a></li><li><a class="nounderline abstract_t">Adams DD, Purves HD. Abnormal responses in the assay of thyrotropin. Proceedings of the University of Otago Medical School 1956; 34:11.</a></li><li><a class="nounderline abstract_t">Smith BR, Hall R. Thyroid-stimulating immunoglobulins in Graves' disease. Lancet 1974; 2:427.</a></li><li><a class="nounderline abstract_t">Adams DD, Fastier FN, Howie JB, et al. Stimulation of the human thyroid by infusions of plasma containing LATS protector. J Clin Endocrinol Metab 1974; 39:826.</a></li><li><a class="nounderline abstract_t">McKenzie JM, Zakarija M. Fetal and neonatal hyperthyroidism and hypothyroidism due to maternal TSH receptor antibodies. Thyroid 1992; 2:155.</a></li><li><a class="nounderline abstract_t">Massart C, Gibassier J, d'Herbomez M. Clinical value of M22-based assays for TSH-receptor antibody (TRAb) in the follow-up of antithyroid drug treated Graves' disease: comparison with the second generation human TRAb assay. Clin Chim Acta 2009; 407:62.</a></li><li><a class="nounderline abstract_t">Zöphel K, Roggenbuck D, von Landenberg P, et al. TSH receptor antibody (TRAb) assays based on the human monoclonal autoantibody M22 are more sensitive than bovine TSH based assays. Horm Metab Res 2010; 42:65.</a></li><li><a class="nounderline abstract_t">Lytton SD, Kahaly GJ. Bioassays for TSH-receptor autoantibodies: an update. Autoimmun Rev 2010; 10:116.</a></li><li><a class="nounderline abstract_t">Shimojo N, Kohno Y, Yamaguchi K, et al. Induction of Graves-like disease in mice by immunization with fibroblasts transfected with the thyrotropin receptor and a class II molecule. Proc Natl Acad Sci U S A 1996; 93:11074.</a></li><li><a class="nounderline abstract_t">Kita M, Ahmad L, Marians RC, et al. Regulation and transfer of a murine model of thyrotropin receptor antibody mediated Graves' disease. Endocrinology 1999; 140:1392.</a></li><li><a class="nounderline abstract_t">Costagliola S, Many MC, Denef JF, et al. Genetic immunization of outbred mice with thyrotropin receptor cDNA provides a model of Graves' disease. J Clin Invest 2000; 105:803.</a></li><li><a class="nounderline abstract_t">Nagayama Y, Kita-Furuyama M, Ando T, et al. A novel murine model of Graves' hyperthyroidism with intramuscular injection of adenovirus expressing the thyrotropin receptor. J Immunol 2002; 168:2789.</a></li><li><a class="nounderline abstract_t">Weetman AP, Yateman ME, Ealey PA, et al. Thyroid-stimulating antibody activity between different immunoglobulin G subclasses. J Clin Invest 1990; 86:723.</a></li><li><a class="nounderline abstract_t">Davies TF, Yeo PP, Evered DC, et al. Value of thyroid-stimulating-antibody determinations in predicting short-term thyrotoxic relapse in Graves' disease. Lancet 1977; 1:1181.</a></li><li><a class="nounderline abstract_t">Wilson R, McKillop JH, Henderson N, et al. The ability of the serum thyrotrophin receptor antibody (TRAb) index and HLA status to predict long-term remission of thyrotoxicosis following medical therapy for Graves' disease. Clin Endocrinol (Oxf) 1986; 25:151.</a></li><li><a class="nounderline abstract_t">Davies TF, Roti E, Braverman LE, DeGroot LJ. Thyroid controversy--stimulating antibodies. J Clin Endocrinol Metab 1998; 83:3777.</a></li><li><a class="nounderline abstract_t">Feldt-Rasmussen U, Schleusener H, Carayon P. Meta-analysis evaluation of the impact of thyrotropin receptor antibodies on long term remission after medical therapy of Graves' disease. J Clin Endocrinol Metab 1994; 78:98.</a></li><li><a class="nounderline abstract_t">Saito T, Endo T, Kawaguchi A, et al. Increased expression of the Na+/I- symporter in cultured human thyroid cells exposed to thyrotropin and in Graves' thyroid tissue. J Clin Endocrinol Metab 1997; 82:3331.</a></li><li><a class="nounderline abstract_t">Vassart G, Dumont JE. The thyrotropin receptor and the regulation of thyrocyte function and growth. Endocr Rev 1992; 13:596.</a></li><li><a class="nounderline abstract_t">Kleinau G, Jaeschke H, Worth CL, et al. Principles and determinants of G-protein coupling by the rhodopsin-like thyrotropin receptor. PLoS One 2010; 5:e9745.</a></li><li><a class="nounderline abstract_t">Latif R, Morshed SA, McCann C, Davies TF. Thyroid Stem Cell Speciation-a Major Role for PKC. Endocrinology 2023; 164.</a></li><li><a class="nounderline abstract_t">Salvi M, Vannucchi G, Campi I, Beck-Peccoz P. Rituximab in the treatment of thyroid eye disease: science fiction? Orbit 2009; 28:251.</a></li><li><a class="nounderline abstract_t">Hegedüs L, Smith TJ, Douglas RS, Nielsen CH. Targeted biological therapies for Graves' disease and thyroid-associated ophthalmopathy. Focus on B-cell depletion with Rituximab. Clin Endocrinol (Oxf) 2011; 74:1.</a></li><li><a class="nounderline abstract_t">Aizawa Y, Yoshida K, Kaise N, et al. Long-term effects of radioiodine on thyrotrophin receptor antibodies in Graves' disease. Clin Endocrinol (Oxf) 1995; 42:517.</a></li><li><a class="nounderline abstract_t">Laurberg P, Wallin G, Tallstedt L, et al. TSH-receptor autoimmunity in Graves' disease after therapy with anti-thyroid drugs, surgery, or radioiodine: a 5-year prospective randomized study. Eur J Endocrinol 2008; 158:69.</a></li><li><a class="nounderline abstract_t">Morshed SA, Latif R, Davies TF. Characterization of thyrotropin receptor antibody-induced signaling cascades. Endocrinology 2009; 150:519.</a></li><li><a class="nounderline abstract_t">Morshed SA, Ando T, Latif R, Davies TF. Neutral antibodies to the TSH receptor are present in Graves' disease and regulate selective signaling cascades. Endocrinology 2010; 151:5537.</a></li><li><a class="nounderline abstract_t">Morshed SA, Ma R, Latif R, Davies TF. Cleavage Region Thyrotropin Receptor Antibodies Influence Thyroid Cell Survival In Vivo. Thyroid 2019; 29:993.</a></li><li><a class="nounderline abstract_t">Morshed SA, Davies TF. Understanding Thyroid Cell Stress. J Clin Endocrinol Metab 2020; 105:e66.</a></li><li><a class="nounderline abstract_t">Núñez Miguel R, Sanders J, Chirgadze DY, et al. Thyroid stimulating autoantibody M22 mimics TSH binding to the TSH receptor leucine rich domain: a comparative structural study of protein-protein interactions. J Mol Endocrinol 2009; 42:381.</a></li><li><a class="nounderline abstract_t">Nagayama Y. Continuous versus discontinuous B-cell epitopes on thyroid-specific autoantigens--thyrotropin receptor and thyroid peroxidase. Eur J Endocrinol 1995; 132:9.</a></li><li><a class="nounderline abstract_t">Vlase H, Graves PN, Magnusson RP, Davies TF. Human autoantibodies to the thyrotropin receptor: recognition of linear, folded, and glycosylated recombinant extracellular domain. J Clin Endocrinol Metab 1995; 80:46.</a></li><li><a class="nounderline abstract_t">Nagayama Y, Rapoport B. Thyroid stimulatory autoantibodies in different patients with autoimmune thyroid disease do not all recognize the same components of the human thyrotropin receptor: selective role of receptor amino acids Ser25-Glu30. J Clin Endocrinol Metab 1992; 75:1425.</a></li><li><a class="nounderline abstract_t">Ando T, Latif R, Daniel S, et al. Dissecting linear and conformational epitopes on the native thyrotropin receptor. Endocrinology 2004; 145:5185.</a></li><li><a class="nounderline abstract_t">Tamai H, Kasagi K, Takaichi Y, et al. Development of spontaneous hypothyroidism in patients with Graves' disease treated with antithyroidal drugs: clinical, immunological, and histological findings in 26 patients. J Clin Endocrinol Metab 1989; 69:49.</a></li><li><a class="nounderline abstract_t">Takasu N, Yamada T, Sato A, et al. Graves' disease following hypothyroidism due to Hashimoto's disease: studies of eight cases. Clin Endocrinol (Oxf) 1990; 33:687.</a></li><li><a class="nounderline abstract_t">Kraiem Z, Baron E, Kahana L, et al. Changes in stimulating and blocking TSH receptor antibodies in a patient undergoing three cycles of transition from hypo to hyper-thyroidism and back to hypothyroidism. Clin Endocrinol (Oxf) 1992; 36:211.</a></li><li><a class="nounderline abstract_t">Tamai H, Ohsako N, Takeno K, et al. Changes in thyroid function in euthyroid subjects with a family history of Graves' disease: a follow-up study of 69 patients. J Clin Endocrinol Metab 1980; 51:1123.</a></li><li><a class="nounderline abstract_t">Mills KH. Regulatory T cells: friend or foe in immunity to infection? Nat Rev Immunol 2004; 4:841.</a></li><li><a class="nounderline abstract_t">Watson PF, Pickerill AP, Davies R, Weetman AP. Analysis of cytokine gene expression in Graves' disease and multinodular goiter. J Clin Endocrinol Metab 1994; 79:355.</a></li><li><a class="nounderline abstract_t">Rapoport B, McLachlan SM. Graves' hyperthyroidism is antibody-mediated but is predominantly a Th1-type cytokine disease. J Clin Endocrinol Metab 2014; 99:4060.</a></li><li><a class="nounderline abstract_t">Mackenzie WA, Davies TF. An intrathyroidal T-cell clone specifically cytotoxic for human thyroid cells. Immunology 1987; 61:101.</a></li><li><a class="nounderline abstract_t">Peng Y, Martin DA, Kenkel J, et al. Innate and adaptive immune response to apoptotic cells. J Autoimmun 2007; 29:303.</a></li><li><a class="nounderline abstract_t">Ban Y, Davies TF, Greenberg DA, et al. Arginine at position 74 of the HLA-DR beta1 chain is associated with Graves' disease. Genes Immun 2004; 5:203.</a></li><li><a class="nounderline abstract_t">Lohr J, Knoechel B, Abbas AK. Regulatory T cells in the periphery. Immunol Rev 2006; 212:149.</a></li><li><a class="nounderline abstract_t">Coles AJ, Wing M, Smith S, et al. Pulsed monoclonal antibody treatment and autoimmune thyroid disease in multiple sclerosis. Lancet 1999; 354:1691.</a></li><li><a class="nounderline abstract_t">Ward DL, Bing-You RG. Autoimmune thyroid dysfunction induced by interferon-alpha treatment for chronic hepatitis C: screening and monitoring recommendations. Endocr Pract 2001; 7:52.</a></li><li><a class="nounderline abstract_t">Fainboim L, Arruvito L. Mechanisms involved in the expansion of Tregs during pregnancy: role of IL-2/STAT5 signalling. J Reprod Immunol 2011; 88:93.</a></li><li><a class="nounderline abstract_t">Siomkajło M, Mizera Ł, Szymczak D, et al. Effect of systemic steroid therapy in Graves' orbitopathy on regulatory T cells and Th17/Treg ratio. J Endocrinol Invest 2021; 44:2475.</a></li><li><a class="nounderline abstract_t">Fields BA, Mariuzza RA. Structure and function of the T-cell receptor: insights from X-ray crystallography. Immunol Today 1996; 17:330.</a></li><li><a class="nounderline abstract_t">Davies TF, Martin A, Concepcion ES, et al. Evidence of limited variability of antigen receptors on intrathyroidal T cells in autoimmune thyroid disease. N Engl J Med 1991; 325:238.</a></li><li><a class="nounderline abstract_t">Davies TF, Concepcion ES, Ben-Nun A, et al. T-cell receptor V gene use in autoimmune thyroid disease: direct assessment by thyroid aspiration. J Clin Endocrinol Metab 1993; 76:660.</a></li><li><a class="nounderline abstract_t">Heufelder AE, Wenzel BE, Scriba PC. Antigen receptor variable region repertoires expressed by T cells infiltrating thyroid, retroorbital, and pretibial tissue in Graves' disease. J Clin Endocrinol Metab 1996; 81:3733.</a></li><li><a class="nounderline abstract_t">Nakashima M, Martin A, Davies TF. Intrathyroidal T cell accumulation in Graves' disease: delineation of mechanisms based on in situ T cell receptor analysis. J Clin Endocrinol Metab 1996; 81:3346.</a></li><li><a class="nounderline abstract_t">Jansson R, Dahlberg PA, Winsa B, et al. The postpartum period constitutes an important risk for the development of clinical Graves' disease in young women. Acta Endocrinol (Copenh) 1987; 116:321.</a></li><li class="breakAll">Davis MM, Buxbaum J. T-cell receptor use in human autoimmune diseases, New York Academy of Sciences, New York 1995.</li><li><a class="nounderline abstract_t">Martin A, Barbesino G, Davies TF. T-cell receptors and autoimmune thyroid disease--signposts for T-cell-antigen driven diseases. Int Rev Immunol 1999; 18:111.</a></li><li><a class="nounderline abstract_t">Mao C, Wang S, Xiao Y, et al. Impairment of regulatory capacity of CD4+CD25+ regulatory T cells mediated by dendritic cell polarization and hyperthyroidism in Graves' disease. J Immunol 2011; 186:4734.</a></li><li><a class="nounderline abstract_t">Pan D, Shin YH, Gopalakrishnan G, et al. Regulatory T cells in Graves' disease. Clin Endocrinol (Oxf) 2009; 71:587.</a></li><li><a class="nounderline abstract_t">Zhong Y, Lu TT, Liu XM, et al. High Levels of Thyroid Hormone Impair Regulatory T Cell Function Via Reduced PD-1 Expression. J Clin Endocrinol Metab 2021; 106:2738.</a></li><li><a class="nounderline abstract_t">Schwartz RH. T cell anergy. Sci Am 1993; 269:62.</a></li><li><a class="nounderline abstract_t">Arnold B, Schönrich G, Hämmerling GJ. Multiple levels of peripheral tolerance. Immunol Today 1993; 14:12.</a></li><li><a class="nounderline abstract_t">Srinivasappa J, Saegusa J, Prabhakar BS, et al. Molecular mimicry: frequency of reactivity of monoclonal antiviral antibodies with normal tissues. J Virol 1986; 57:397.</a></li><li><a class="nounderline abstract_t">Wenzel BE, Heesemann J, Wenzel KW, Scriba PC. Antibodies to plasmid-encoded proteins of enteropathogenic Yersinia in patients with autoimmune thyroid disease. Lancet 1988; 1:56.</a></li><li><a class="nounderline abstract_t">Brix TH, Hansen PS, Hegedüs L, Wenzel BE. Too early to dismiss Yersinia enterocolitica infection in the aetiology of Graves' disease: evidence from a twin case-control study. Clin Endocrinol (Oxf) 2008; 69:491.</a></li><li><a class="nounderline abstract_t">Burch HB, Nagy EV, Lukes YG, et al. Nucleotide and amino acid homology between the human thyrotropin receptor and the HIV-1 Nef protein: identification and functional analysis. Biochem Biophys Res Commun 1991; 181:498.</a></li><li><a class="nounderline abstract_t">Heufelder AE, Goellner JR, Wenzel BE, Bahn RS. Immunohistochemical detection and localization of a 72-kilodalton heat shock protein in autoimmune thyroid disease. J Clin Endocrinol Metab 1992; 74:724.</a></li><li><a class="nounderline abstract_t">Bottazzo GF, Pujol-Borrell R, Hanafusa T, Feldmann M. Role of aberrant HLA-DR expression and antigen presentation in induction of endocrine autoimmunity. Lancet 1983; 2:1115.</a></li><li><a class="nounderline abstract_t">Hammerstad SS, Stefan M, Blackard J, et al. Hepatitis C Virus E2 Protein Induces Upregulation of IL-8 Pathways and Production of Heat Shock Proteins in Human Thyroid Cells. J Clin Endocrinol Metab 2017; 102:689.</a></li><li><a class="nounderline abstract_t">Kawakami Y, Kuzuya N, Watanabe T, et al. Induction of experimental thyroiditis in mice by recombinant interferon gamma administration. Acta Endocrinol (Copenh) 1990; 122:41.</a></li><li><a class="nounderline abstract_t">Neufeld DS, Platzer M, Davies TF. Reovirus induction of MHC class II antigen in rat thyroid cells. Endocrinology 1989; 124:543.</a></li><li><a class="nounderline abstract_t">Khoury EL, Pereira L, Greenspan FS. Induction of HLA-DR expression on thyroid follicular cells by cytomegalovirus infection in vitro. Evidence for a dual mechanism of induction. Am J Pathol 1991; 138:1209.</a></li><li><a class="nounderline abstract_t">Londei M, Lamb JR, Bottazzo GF, Feldmann M. Epithelial cells expressing aberrant MHC class II determinants can present antigen to cloned human T cells. Nature 1984; 312:639.</a></li><li><a class="nounderline abstract_t">Kimura H, Davies TF. Thyroid-specific T cells in the normal Wistar rat. II. T cell clones interact with cloned wistar rat thyroid cells and provide direct evidence for autoantigen presentation by thyroid epithelial cells. Clin Immunol Immunopathol 1991; 58:195.</a></li><li><a class="nounderline abstract_t">Horwitz MS, Bradley LM, Harbertson J, et al. Diabetes induced by Coxsackie virus: initiation by bystander damage and not molecular mimicry. Nat Med 1998; 4:781.</a></li><li><a class="nounderline abstract_t">Arata N, Ando T, Unger P, Davies TF. By-stander activation in autoimmune thyroiditis: studies on experimental autoimmune thyroiditis in the GFP+ fluorescent mouse. Clin Immunol 2006; 121:108.</a></li><li><a class="nounderline abstract_t">Stenszky V, Kozma L, Balázs C, et al. The genetics of Graves' disease: HLA and disease susceptibility. J Clin Endocrinol Metab 1985; 61:735.</a></li><li><a class="nounderline abstract_t">Tomer Y, Ban Y, Concepcion E, et al. Common and unique susceptibility loci in Graves and Hashimoto diseases: results of whole-genome screening in a data set of 102 multiplex families. Am J Hum Genet 2003; 73:736.</a></li><li><a class="nounderline abstract_t">Tomer Y, Davies TF. Searching for the autoimmune thyroid disease susceptibility genes: from gene mapping to gene function. Endocr Rev 2003; 24:694.</a></li><li><a class="nounderline abstract_t">Villanueva R, Greenberg DA, Davies TF, Tomer Y. Sibling recurrence risk in autoimmune thyroid disease. Thyroid 2003; 13:761.</a></li><li><a class="nounderline abstract_t">Heward JM, Allahabadia A, Armitage M, et al. The development of Graves' disease and the CTLA-4 gene on chromosome 2q33. J Clin Endocrinol Metab 1999; 84:2398.</a></li><li><a class="nounderline abstract_t">Chen QY, Huang W, She JX, et al. HLA-DRB1*08, DRB1*03/DRB3*0101, and DRB3*0202 are susceptibility genes for Graves' disease in North American Caucasians, whereas DRB1*07 is protective. J Clin Endocrinol Metab 1999; 84:3182.</a></li><li><a class="nounderline abstract_t">Jacobson EM, Huber A, Tomer Y. The HLA gene complex in thyroid autoimmunity: from epidemiology to etiology. J Autoimmun 2008; 30:58.</a></li><li><a class="nounderline abstract_t">Ho SC, Goh SS, Khoo DH. Association of Graves' disease with intragenic polymorphism of the thyrotropin receptor gene in a cohort of Singapore patients of multi-ethnic origins. Thyroid 2003; 13:523.</a></li><li><a class="nounderline abstract_t">Hiratani H, Bowden DW, Ikegami S, et al. Multiple SNPs in intron 7 of thyrotropin receptor are associated with Graves' disease. J Clin Endocrinol Metab 2005; 90:2898.</a></li><li><a class="nounderline abstract_t">Yin X, Latif R, Bahn R, et al. Influence of the TSH receptor gene on susceptibility to Graves' disease and Graves' ophthalmopathy. Thyroid 2008; 18:1201.</a></li><li><a class="nounderline abstract_t">Davies TF, Yin X, Latif R. The genetics of the thyroid stimulating hormone receptor: history and relevance. Thyroid 2010; 20:727.</a></li><li><a class="nounderline abstract_t">Ban Y, Greenberg DA, Concepcion E, et al. Amino acid substitutions in the thyroglobulin gene are associated with susceptibility to human and murine autoimmune thyroid disease. Proc Natl Acad Sci U S A 2003; 100:15119.</a></li><li><a class="nounderline abstract_t">Rockweiler NB, Ramu A, Nagirnaja L, et al. The origins and functional effects of postzygotic mutations throughout the human life span. Science 2023; 380:eabn7113.</a></li><li><a class="nounderline abstract_t">Menconi F, Hasham A, Tomer Y. Environmental triggers of thyroiditis: hepatitis C and interferon-α. J Endocrinol Invest 2011; 34:78.</a></li><li><a class="nounderline abstract_t">Humphrey M, Mosca J, Baker JR Jr, et al. Absence of retroviral sequences in Graves' disease. Lancet 1991; 337:17.</a></li><li><a class="nounderline abstract_t">Neumann-Haefelin D, Fleps U, Renne R, Schweizer M. Foamy viruses. Intervirology 1993; 35:196.</a></li><li><a class="nounderline abstract_t">Inaba H, Aizawa T. Coronavirus Disease 2019 and the Thyroid - Progress and Perspectives. Front Endocrinol (Lausanne) 2021; 12:708333.</a></li><li><a class="nounderline abstract_t">Murugan AK, Alzahrani AS. SARS-CoV-2 plays a pivotal role in inducing hyperthyroidism of Graves' disease. Endocrine 2021; 73:243.</a></li><li><a class="nounderline abstract_t">Tomer Y, Davies TF. Infection, thyroid disease, and autoimmunity. Endocr Rev 1993; 14:107.</a></li><li><a class="nounderline abstract_t">Yin X, Sachidanandam R, Morshed S, et al. mRNA-Seq reveals novel molecular mechanisms and a robust fingerprint in Graves' disease. J Clin Endocrinol Metab 2014; 99:E2076.</a></li><li><a class="nounderline abstract_t">Weider T, Richardson SJ, Morgan NG, et al. Upregulation of HLA Class I and Antiviral Tissue Responses in Hashimoto's Thyroiditis. Thyroid 2020; 30:432.</a></li><li><a class="nounderline abstract_t">Sonino N, Girelli ME, Boscaro M, et al. Life events in the pathogenesis of Graves' disease. A controlled study. Acta Endocrinol (Copenh) 1993; 128:293.</a></li><li><a class="nounderline abstract_t">Kung AW. Life events, daily stresses and coping in patients with Graves' disease. Clin Endocrinol (Oxf) 1995; 42:303.</a></li><li><a class="nounderline abstract_t">Matos-Santos A, Nobre EL, Costa JG, et al. Relationship between the number and impact of stressful life events and the onset of Graves' disease and toxic nodular goitre. Clin Endocrinol (Oxf) 2001; 55:15.</a></li><li><a class="nounderline abstract_t">Kincade PW, Medina KL, Smithson G, Scott DC. Pregnancy: a clue to normal regulation of B lymphopoiesis. Immunol Today 1994; 15:539.</a></li><li><a class="nounderline abstract_t">Paavonen T. Hormonal regulation of immune responses. Ann Med 1994; 26:255.</a></li><li><a class="nounderline abstract_t">Da Silva JA. Sex hormones, glucocorticoids and autoimmunity: facts and hypotheses. Ann Rheum Dis 1995; 54:6.</a></li><li><a class="nounderline abstract_t">Yin X, Latif R, Tomer Y, Davies TF. Thyroid epigenetics: X chromosome inactivation in patients with autoimmune thyroid disease. Ann N Y Acad Sci 2007; 1110:193.</a></li><li><a class="nounderline abstract_t">Cheng MI, Li JH, Riggan L, et al. The X-linked epigenetic regulator UTX controls NK cell-intrinsic sex differences. Nat Immunol 2023; 24:780.</a></li><li><a class="nounderline abstract_t">Markle JG, Frank DN, Mortin-Toth S, et al. Sex differences in the gut microbiome drive hormone-dependent regulation of autoimmunity. Science 2013; 339:1084.</a></li><li><a class="nounderline abstract_t">Su X, Yin X, Liu Y, et al. Gut Dysbiosis Contributes to the Imbalance of Treg and Th17 Cells in Graves' Disease Patients by Propionic Acid. J Clin Endocrinol Metab 2020; 105.</a></li><li><a class="nounderline abstract_t">Docimo G, Cangiano A, Romano RM, et al. The Human Microbiota in Endocrinology: Implications for Pathophysiology, Treatment, and Prognosis in Thyroid Diseases. Front Endocrinol (Lausanne) 2020; 11:586529.</a></li><li><a class="nounderline abstract_t">Biscarini F, Masetti G, Muller I, et al. Gut Microbiome Associated With Graves Disease and Graves Orbitopathy: The INDIGO Multicenter European Study. J Clin Endocrinol Metab 2023; 108:2065.</a></li><li><a class="nounderline abstract_t">Stramazzo I, Capriello S, Filardo S, et al. Microbiota and Thyroid Disease: An Updated Systematic Review. Adv Exp Med Biol 2023; 1370:125.</a></li><li><a class="nounderline abstract_t">Prummel MF, Wiersinga WM. Smoking and risk of Graves' disease. JAMA 1993; 269:479.</a></li><li><a class="nounderline abstract_t">Holm IA, Manson JE, Michels KB, et al. Smoking and other lifestyle factors and the risk of Graves' hyperthyroidism. Arch Intern Med 2005; 165:1606.</a></li><li><a class="nounderline abstract_t">Bartalena L, Tanda ML. Clinical practice. Graves' ophthalmopathy. N Engl J Med 2009; 360:994.</a></li><li><a class="nounderline abstract_t">Stan MN, Bahn RS. Risk factors for development or deterioration of Graves' ophthalmopathy. Thyroid 2010; 20:777.</a></li><li><a class="nounderline abstract_t">Weetman AP. Immunity, thyroid function and pregnancy: molecular mechanisms. Nat Rev Endocrinol 2010; 6:311.</a></li><li><a class="nounderline abstract_t">Stagnaro-Green A. Postpartum thyroiditis. Best Pract Res Clin Endocrinol Metab 2004; 18:303.</a></li><li><a class="nounderline abstract_t">Ando T, Davies TF. Clinical Review 160: Postpartum autoimmune thyroid disease: the potential role of fetal microchimerism. J Clin Endocrinol Metab 2003; 88:2965.</a></li><li><a class="nounderline abstract_t">Bartalena L, Bogazzi F, Martino E. Amiodarone-induced thyrotoxicosis: a difficult diagnostic and therapeutic challenge. Clin Endocrinol (Oxf) 2002; 56:23.</a></li><li><a class="nounderline abstract_t">Burikhanov RB, Matsuzaki S. Excess iodine induces apoptosis in the thyroid of goitrogen-pretreated rats in vivo. Thyroid 2000; 10:123.</a></li><li><a class="nounderline abstract_t">Mandac JC, Chaudhry S, Sherman KE, Tomer Y. The clinical and physiological spectrum of interferon-alpha induced thyroiditis: toward a new classification. Hepatology 2006; 43:661.</a></li><li><a class="nounderline abstract_t">Aranha AA, Amer S, Reda ES, et al. Autoimmune thyroid disease in the use of alemtuzumab for multiple sclerosis: a review. Endocr Pract 2013; 19:821.</a></li><li><a class="nounderline abstract_t">de Filette J, Andreescu CE, Cools F, et al. A Systematic Review and Meta-Analysis of Endocrine-Related Adverse Events Associated with Immune Checkpoint Inhibitors. Horm Metab Res 2019; 51:145.</a></li></ol></div><div id="topicVersionRevision">Topic 7841 Version 15.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1759536" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Regional stimulation of thyroid epithelial cells in Graves' disease by lymphocytic aggregates and plasma cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17972347" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : How apoptosis got the immune system in shape.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18324486" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Identification of apoptotic proteins in thyroid gland from patients with Graves' disease and Hashimoto's thyroiditis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16075037" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Thyrotropin receptor-associated diseases: from adenomata to Graves disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19328414" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : The thyroid-stimulating hormone receptor: impact of thyroid-stimulating hormone and thyroid-stimulating hormone receptor antibodies on multimerization, cleavage, and signaling.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37199228" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Emerging roles of brain tanycytes in regulating blood-hypothalamus barrier plasticity and energy homeostasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12122113" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Thyroid-stimulating autoantibodies in Graves disease preferentially recognize the free A subunit, not the thyrotropin holoreceptor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21642385" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Association of an SNP with intrathymic transcription of TSHR and Graves' disease: a role for defective thymic tolerance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25122677" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Genetic-epigenetic dysregulation of thymic TSH receptor gene expression triggers thyroid autoimmunity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3011319" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : TSH receptor antibody synthesis by thyroid lymphocytes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Abnormal responses in the assay of thyrotropin</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4137321" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Thyroid-stimulating immunoglobulins in Graves' disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4425101" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Stimulation of the human thyroid by infusions of plasma containing LATS protector.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1356056" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Fetal and neonatal hyperthyroidism and hypothyroidism due to maternal TSH receptor antibodies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19576193" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Clinical value of M22-based assays for TSH-receptor antibody (TRAb) in the follow-up of antithyroid drug treated Graves' disease: comparison with the second generation human TRAb assay.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19830651" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : TSH receptor antibody (TRAb) assays based on the human monoclonal autoantibody M22 are more sensitive than bovine TSH based assays.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20807591" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Bioassays for TSH-receptor autoantibodies: an update.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8855311" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Induction of Graves-like disease in mice by immunization with fibroblasts transfected with the thyrotropin receptor and a class II molecule.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10067867" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Regulation and transfer of a murine model of thyrotropin receptor antibody mediated Graves' disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10727449" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Genetic immunization of outbred mice with thyrotropin receptor cDNA provides a model of Graves' disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11884447" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : A novel murine model of Graves' hyperthyroidism with intramuscular injection of adenovirus expressing the thyrotropin receptor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2168443" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Thyroid-stimulating antibody activity between different immunoglobulin G subclasses.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/68278" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Value of thyroid-stimulating-antibody determinations in predicting short-term thyrotoxic relapse in Graves' disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3491692" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : The ability of the serum thyrotrophin receptor antibody (TRAb) index and HLA status to predict long-term remission of thyrotoxicosis following medical therapy for Graves' disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9814446" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Thyroid controversy--stimulating antibodies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8288723" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Meta-analysis evaluation of the impact of thyrotropin receptor antibodies on long term remission after medical therapy of Graves' disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9329364" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Increased expression of the Na+/I- symporter in cultured human thyroid cells exposed to thyrotropin and in Graves' thyroid tissue.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1425489" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : The thyrotropin receptor and the regulation of thyrocyte function and growth.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20305779" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Principles and determinants of G-protein coupling by the rhodopsin-like thyrotropin receptor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37120783" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Thyroid Stem Cell Speciation-a Major Role for PKC.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19839884" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Rituximab in the treatment of thyroid eye disease: science fiction?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20455896" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Targeted biological therapies for Graves' disease and thyroid-associated ophthalmopathy. Focus on B-cell depletion with Rituximab.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7621571" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Long-term effects of radioiodine on thyrotrophin receptor antibodies in Graves' disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18166819" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : TSH-receptor autoimmunity in Graves' disease after therapy with anti-thyroid drugs, surgery, or radioiodine: a 5-year prospective randomized study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18719020" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Characterization of thyrotropin receptor antibody-induced signaling cascades.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20844004" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Neutral antibodies to the TSH receptor are present in Graves' disease and regulate selective signaling cascades.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31025602" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Cleavage Region Thyrotropin Receptor Antibodies Influence Thyroid Cell Survival In Vivo.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31711166" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Understanding Thyroid Cell Stress.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19221175" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Thyroid stimulating autoantibody M22 mimics TSH binding to the TSH receptor leucine rich domain: a comparative structural study of protein-protein interactions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7531577" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Continuous versus discontinuous B-cell epitopes on thyroid-specific autoantigens--thyrotropin receptor and thyroid peroxidase.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7829638" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Human autoantibodies to the thyrotropin receptor: recognition of linear, folded, and glycosylated recombinant extracellular domain.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1361193" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Thyroid stimulatory autoantibodies in different patients with autoimmune thyroid disease do not all recognize the same components of the human thyrotropin receptor: selective role of receptor amino acids Ser25-Glu30.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15297445" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Dissecting linear and conformational epitopes on the native thyrotropin receptor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2471711" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Development of spontaneous hypothyroidism in patients with Graves' disease treated with antithyroidal drugs: clinical, immunological, and histological findings in 26 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1982861" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Graves' disease following hypothyroidism due to Hashimoto's disease: studies of eight cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1637398" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Changes in stimulating and blocking TSH receptor antibodies in a patient undergoing three cycles of transition from hypo to hyper-thyroidism and back to hypothyroidism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6774999" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Changes in thyroid function in euthyroid subjects with a family history of Graves' disease: a follow-up study of 69 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15516964" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Regulatory T cells: friend or foe in immunity to infection?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8045947" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Analysis of cytokine gene expression in Graves' disease and multinodular goiter.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25210884" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Graves' hyperthyroidism is antibody-mediated but is predominantly a Th1-type cytokine disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3495484" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : An intrathyroidal T-cell clone specifically cytotoxic for human thyroid cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17888627" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Innate and adaptive immune response to apoptotic cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15029234" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Arginine at position 74 of the HLA-DR beta1 chain is associated with Graves' disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16903912" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Regulatory T cells in the periphery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10568572" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Pulsed monoclonal antibody treatment and autoimmune thyroid disease in multiple sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11250770" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Autoimmune thyroid dysfunction induced by interferon-alpha treatment for chronic hepatitis C: screening and monitoring recommendations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21329987" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Mechanisms involved in the expansion of Tregs during pregnancy: role of IL-2/STAT5 signalling.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33866536" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Effect of systemic steroid therapy in Graves' orbitopathy on regulatory T cells and Th17/Treg ratio.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8763819" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Structure and function of the T-cell receptor: insights from X-ray crystallography.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1829139" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Evidence of limited variability of antigen receptors on intrathyroidal T cells in autoimmune thyroid disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8445022" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : T-cell receptor V gene use in autoimmune thyroid disease: direct assessment by thyroid aspiration.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8855831" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Antigen receptor variable region repertoires expressed by T cells infiltrating thyroid, retroorbital, and pretibial tissue in Graves' disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8784095" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Intrathyroidal T cell accumulation in Graves' disease: delineation of mechanisms based on in situ T cell receptor analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3687319" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : The postpartum period constitutes an important risk for the development of clinical Graves' disease in young women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3687319" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : The postpartum period constitutes an important risk for the development of clinical Graves' disease in young women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10614741" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : T-cell receptors and autoimmune thyroid disease--signposts for T-cell-antigen driven diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21398613" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Impairment of regulatory capacity of CD4+CD25+ regulatory T cells mediated by dendritic cell polarization and hyperthyroidism in Graves' disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19222488" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Regulatory T cells in Graves' disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33758937" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : High Levels of Thyroid Hormone Impair Regulatory T Cell Function Via Reduced PD-1 Expression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8351512" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : T cell anergy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8442855" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Multiple levels of peripheral tolerance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3753614" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Molecular mimicry: frequency of reactivity of monoclonal antiviral antibodies with normal tissues.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2891918" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Antibodies to plasmid-encoded proteins of enteropathogenic Yersinia in patients with autoimmune thyroid disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18284638" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Too early to dismiss Yersinia enterocolitica infection in the aetiology of Graves' disease: evidence from a twin case-control study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1958218" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Nucleotide and amino acid homology between the human thyrotropin receptor and the HIV-1 Nef protein: identification and functional analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1548334" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Immunohistochemical detection and localization of a 72-kilodalton heat shock protein in autoimmune thyroid disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6138647" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Role of aberrant HLA-DR expression and antigen presentation in induction of endocrine autoimmunity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27860532" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Hepatitis C Virus E2 Protein Induces Upregulation of IL-8 Pathways and Production of Heat Shock Proteins in Human Thyroid Cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2106189" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Induction of experimental thyroiditis in mice by recombinant interferon gamma administration.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2491810" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Reovirus induction of MHC class II antigen in rat thyroid cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1850961" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Induction of HLA-DR expression on thyroid follicular cells by cytomegalovirus infection in vitro. Evidence for a dual mechanism of induction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6334239" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Epithelial cells expressing aberrant MHC class II determinants can present antigen to cloned human T cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1702377" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Thyroid-specific T cells in the normal Wistar rat. II. T cell clones interact with cloned wistar rat thyroid cells and provide direct evidence for autoantigen presentation by thyroid epithelial cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9662368" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Diabetes induced by Coxsackie virus: initiation by bystander damage and not molecular mimicry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16916620" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : By-stander activation in autoimmune thyroiditis: studies on experimental autoimmune thyroiditis in the GFP+ fluorescent mouse.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3861611" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : The genetics of Graves' disease: HLA and disease susceptibility.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12973666" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Common and unique susceptibility loci in Graves and Hashimoto diseases: results of whole-genome screening in a data set of 102 multiplex families.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14570752" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Searching for the autoimmune thyroid disease susceptibility genes: from gene mapping to gene function.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14558919" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Sibling recurrence risk in autoimmune thyroid disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10404810" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : The development of Graves' disease and the CTLA-4 gene on chromosome 2q33.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10487684" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : HLA-DRB1*08, DRB1*03/DRB3*0101, and DRB3*0202 are susceptibility genes for Graves' disease in North American Caucasians, whereas DRB1*07 is protective.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18178059" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : The HLA gene complex in thyroid autoimmunity: from epidemiology to etiology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12930595" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Association of Graves' disease with intragenic polymorphism of the thyrotropin receptor gene in a cohort of Singapore patients of multi-ethnic origins.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15741259" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Multiple SNPs in intron 7 of thyrotropin receptor are associated with Graves' disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18925838" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Influence of the TSH receptor gene on susceptibility to Graves' disease and Graves' ophthalmopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20578897" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : The genetics of the thyroid stimulating hormone receptor: history and relevance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14657345" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Amino acid substitutions in the thyroglobulin gene are associated with susceptibility to human and murine autoimmune thyroid disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37053313" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : The origins and functional effects of postzygotic mutations throughout the human life span.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21297381" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Environmental triggers of thyroiditis: hepatitis C and interferon-α.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1670652" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Absence of retroviral sequences in Graves' disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8407246" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Foamy viruses.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34276567" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : Coronavirus Disease 2019 and the Thyroid - Progress and Perspectives.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34106438" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : SARS-CoV-2 plays a pivotal role in inducing hyperthyroidism of Graves' disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8491150" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : Infection, thyroid disease, and autoimmunity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24971664" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : mRNA-Seq reveals novel molecular mechanisms and a robust fingerprint in Graves' disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31910110" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : Upregulation of HLA Class I and Antiviral Tissue Responses in Hashimoto's Thyroiditis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8498147" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : Life events in the pathogenesis of Graves' disease. A controlled study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7758236" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : Life events, daily stresses and coping in patients with Graves' disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11453947" id="rid108" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>109 : Relationship between the number and impact of stressful life events and the onset of Graves' disease and toxic nodular goitre.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7802925" id="rid109" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>110 : Pregnancy: a clue to normal regulation of B lymphopoiesis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7946244" id="rid110" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>111 : Hormonal regulation of immune responses.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7880125" id="rid111" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>112 : Sex hormones, glucocorticoids and autoimmunity: facts and hypotheses.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17911434" id="rid112" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>113 : Thyroid epigenetics: X chromosome inactivation in patients with autoimmune thyroid disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36928413" id="rid113" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>114 : The X-linked epigenetic regulator UTX controls NK cell-intrinsic sex differences.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23328391" id="rid114" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>115 : Sex differences in the gut microbiome drive hormone-dependent regulation of autoimmunity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32785703" id="rid115" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>116 : Gut Dysbiosis Contributes to the Imbalance of Treg and Th17 Cells in Graves' Disease Patients by Propionic Acid.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33343507" id="rid116" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>117 : The Human Microbiota in Endocrinology: Implications for Pathophysiology, Treatment, and Prognosis in Thyroid Diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36683389" id="rid117" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>118 : Gut Microbiome Associated With Graves Disease and Graves Orbitopathy: The INDIGO Multicenter European Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36971966" id="rid118" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>119 : Microbiota and Thyroid Disease: An Updated Systematic Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8419666" id="rid119" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>120 : Smoking and risk of Graves' disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16043678" id="rid120" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>121 : Smoking and other lifestyle factors and the risk of Graves' hyperthyroidism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19264688" id="rid121" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>122 : Clinical practice. Graves' ophthalmopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20578901" id="rid122" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>123 : Risk factors for development or deterioration of Graves' ophthalmopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20421883" id="rid123" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>124 : Immunity, thyroid function and pregnancy: molecular mechanisms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15157842" id="rid124" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>125 : Postpartum thyroiditis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12843128" id="rid125" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>126 : Clinical Review 160: Postpartum autoimmune thyroid disease: the potential role of fetal microchimerism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11849242" id="rid126" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>127 : Amiodarone-induced thyrotoxicosis: a difficult diagnostic and therapeutic challenge.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10718548" id="rid127" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>128 : Excess iodine induces apoptosis in the thyroid of goitrogen-pretreated rats in vivo.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16557537" id="rid128" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>129 : The clinical and physiological spectrum of interferon-alpha induced thyroiditis: toward a new classification.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23757618" id="rid129" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>130 : Autoimmune thyroid disease in the use of alemtuzumab for multiple sclerosis: a review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30861560" id="rid130" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>131 : A Systematic Review and Meta-Analysis of Endocrine-Related Adverse Events Associated with Immune Checkpoint Inhibitors.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
